Start here if you're new
what it is
Greenwich LifeSciences is trying to stop breast cancer from coming back after surgery.
how it gets paid
Last year Greenwich Lifesci made n/a in revenue. GP2 clinical development was the main engine at $0.0M, or 100% of sales.
what just happened
FY 2024 EPS was -$1.21, worse than -$0.69 in 2023.
At a glance
B balance sheet — gets the job done, barely
70/100 earnings predictability — reasonably predictable
-$1.21 fy2024 eps est
2.0% operating margin
1.15 beta
xvary composite: 56/100 — below average
What they do
Greenwich LifeSciences is trying to stop breast cancer from coming back after surgery.
Phase IIb trial (mid-stage human test) showed no recurrences after a median five years in the HER2/neu 3+ group (a breast-cancer marker). You are buying one idea, not a catalog. There are 4 employees and one lead program, so every data read matters.
How they make money
n/a
annual revenue
GP2 clinical development
$0.0M
Phase IIb data
$0.0M
Phase III preparation
$0.0M
Corporate overhead
$0.0M
The products that matter
prevents cancer recurrence
GLSI-100 (GP2)
500+ patients enrolled
this is the whole company. it is the only clinical asset, and management said the Phase III program is screening over 800 patients a year.
single asset
Key numbers
-$1.21
fy2024 eps est
n/a
fy rev est
n/a
trailing p/e
n/a
dividend yield
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 2 — safer than 80% of stocks
- price stability 5 / 100
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for GLSI right now.
source: institutional data · return history unavailable
What just happened
missed estimates
FY 2024 EPS was -$1.21, worse than -$0.69 in 2023.
The company is still pre-revenue. Q4 2024 was the weakest quarter in the table at -$0.62 per share, versus -$0.20 a year earlier.
$1.21
eps
2.0%
operating margin
n/a
n/a
the number that mattered
The number that mattered was -$1.21. Losses widened from -$0.69 in 2023 to -$1.21 in 2024.
source: company filings, 2024
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
The #1 risk here is Phase III failure for GP2. This company has one late-stage asset, no revenue, and a $370M valuation resting on the same clinical readout.
med
Phase III trial failure
GLSI-100 is the whole story. If the trial fails, there is no second act sitting behind it.
Impact: most of the $370M market cap is exposed to one clinical outcome.
med
cash burn and dilution
The company reported a $15.8M net loss, held $12.5M in cash, and burned $9.5M annually. If the study runs longer than expected, new capital likely arrives before new revenue.
Impact: more shares outstanding can reduce your upside even if the science stays on track.
med
better-funded competitors move faster
A November 2025 competitive analysis called MacroGenics the clear winner because it was further along and more de-risked. In biotech, being right later is sometimes the same as being wrong.
Impact: even a good asset can lose strategic value if competing programs become the preferred option first.
A forced capital raise or a weak trial update would hit a company with no revenue, a thin float, and a valuation built almost entirely on GP2.
source: institutional data · regulatory filings · risk analysis
Pay attention to
catalyst
FLAMINGO-01 enrollment pace
The company said screening moved above 800 patients a year in March 2026. Faster screening is not just good optics — it is how you shorten the wait for the number that matters.
financing
cash runway into 2027
With $12.5M in cash against a $9.5M annual burn, you should read every update through one lens: does current cash still get the company where it says it is going.
float
post-lock-up selling pressure
The insider lock-up extends through September 2026. After that, even modest selling can matter because the float is restricted and liquidity is thin.
science
whether GP2 keeps its edge
The company is a one-program story, and a 2025 analysis already framed MacroGenics as more mature and more de-risked. If competing data gets stronger, the market will notice before approval decisions do.
Analyst rankings
earnings predictability
70 / 100
For a pre-revenue biotech, 70/100 is unusually steady. In human-speak, analysts think the losses are fairly visible even if the stock is not.
risk rank
2
This ranking says the balance sheet is not in immediate distress. It does not mean the clinical outcome is safe.
source: institutional data
Institutional activity
institutional ownership data for GLSI is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$32
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive